Deepanjali

Deepanjali

Active Director Director DIN 05305064
DIN 05305064 First appointment Jul 2012 Primary industry Chemicals
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Jul 2012
Shareholding value •••• Premium profile

About Deepanjali

Data last updated:

Deepanjali is a Director at Anstiss Pharmaceuticals Private Limited (since 2012). The company operates in Chemicals. Anstiss Pharmaceuticals Private Limited reported revenue of ₹61.9 Lakh (FY 2025).

DIN 05305064
Primary Designation Director
Industry Chemicals
First Appointment 12 Jul 2012
Oldest Company Age 14 yrs
Largest company Anstiss Pharmaceuticals Private Limited · ₹61.9 Lakh (FY 2025)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director12 Jul 20122012₹61.9 Lakh (FY 2025)Active

Board colleagues of Deepanjali

NameDINCompanyDesignation
Vivek Verma05305035Anstiss Pharmaceuticals Private LimitedDirector

Directorship timeline

Open interactive timeline →
Anstiss Pharmaceuticals Private Limited
Premium access

Shareholding and investment profile for Deepanjali

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Deepanjali

Deepanjali currently holds 1 directorship: Anstiss Pharmaceuticals Private Limited (Director, since 12 Jul 2012, revenue ₹61.9 Lakh (FY 2025)).

Deepanjali was first appointed on 12 Jul 2012 as Director at Anstiss Pharmaceuticals Private Limited.

The current boards of Deepanjali's companies include Vivek Verma (Anstiss Pharmaceuticals Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available